NEW YORK, Dec 4 – Incyte said Monday it had licensed LifeSeq gold and its ZooSeq animal model database to Sumitomo Pharmaceuticals and Sankyo of Tokyo, Japan.
Researchers at both companies will become the first Incyte customers to access LifeSeq through Incyte’s website, Incyte.com. Incyte.com uses encryption technologies that are used in online commercial transactions to protect the security of data queries and other information.
Financial terms of the agreements were not disclosed.
" We are pleased to continue our penetration of the Japanese market," Incyte CEO Roy Whitfield said in a statement referring to the Sumitomo deal.
Sankyo is Japan’s second-largest pharmaceutical company. Sumitomo Pharmaceuticals, a subsidiary of the $103 billion trading giant Sumitomo, was recently spun off from Sumitomo Chemicals.
This is the second collaboration a Sumitomo subsidiary has formed with a Western genomic information company in the last month. In November, Viaken announced it had signed an agreement with SC Biosciences to jointly explore marketing opportunities in Japan for its bioinformatics hosting platforms.